Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia
Clinical trial NCT05453500 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05453500
- Sponsor
- University of Washington
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-03-27
- Primary completion
- 2026-04-28
- Enrollment
- 32
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.